Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: Preliminary analysis of retrospective data

American Journal of Geriatric Psychiatry

Volumn 12, Issue 4, 2004, Pages 437-439

  Nasrallah, Henry A ^a   White, Thantween ^b   Nasrallah, Amelia T ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTROPHIC FACTOR; OLANZAPINE; RISPERIDONE;

AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INDICATION; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; STATISTICAL ANALYSIS;

EID: 3042729941     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200407000-00012     Document Type: Article

References (10)

1. Pearslon GD, Petty RG: Late-life-onset psychoses, in Textbook of Geriatric Neuropsychiatry. Edited by Coffey CE, Cummings JL. Washington, DC, 1994, pp 261-278
2. Jeste DV, Lacrojp, Baily A, et al: Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47:716-719
3. Ballesteros J, Gonzalez-Pinto A, Bulbena A: Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol 2000; 20:188-194
4. Rovner BW, German PS, Brant LJ, et al: Depression and increased risk of mortality in the nursing home patient. Am J Med 1993; 94:19S-22S
5. Pueskins J: Risperidone in the treatment of chronic schizophrenia patients: a multi-national, multicenter, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166:712-726
6. Beasley CM, Tollegson G, Tran P, et al: Olanzapine versus placebo and haloperidol: acute-phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-124
7. Mahadik SP, Terry A, Hill WD, et al: Neuroprotective actions of olanzapine in rats: cholinergic function. Biol Psychiatry 2000; 47:20S-21S
8. Mahadik SP, Evans DR, Terry A, et al: Differential effects of risperidone and haloperidol on cognitive performance in rats and possible mechanisms of action (abstract). Biol Psychiatry 2001; 49:133S
9. Nasrallah HA, Mahadik SP, Evans D, et al: Are atypical antipsychotics neuroprotective? evidence from animal and human studies (abstract). Biol Psychiatry 2002; 51:2S
10. Parikh V, Evans DR, Khan MM, et al: Nerve growth factors in never-medicated, first-episode psychiatric and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res 2003; 60:117-123